Evidence map›Paper›PMID 34638254›Full record

ArticleCancers2021

Biological Impact of Target Fragments on Proton Treatment Plans: An Analysis Based on the Current Cross-Section Data and a Full Mixed Field Approach.

Elettra Valentina Bellinzona, Leszek Grzanka, Andrea Attili, Francesco Tommasino, Thomas Friedrich, Michael Krämer, Michael Scholz, Giuseppe Battistoni, Alessia Embriaco, Davide Chiappara and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 11 citations in OpenAlex.

  1. Track Structure-Based Simulations on DNA Damage Induced by Diverse Isotopes.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Elettra Valentina BellinzonaTrento Institute for Fundamental Physics and Applications (TIFPA), National Institute for Nuclear Physics, (INFN), 38123 Trento, Italy.ORCID 0000-0002-7698-2800
Leszek GrzankaThe Department of Radiation Research and Proton Radiotherapy, Institute of Nuclear Physics, Polish Academy of Sciences, 31-342 Krakow, Poland.ORCID 0000-0002-3599-854X
Andrea Attili"Roma Tre" Section, INFN-National Institute for Nuclear Physics, 00146 Roma, Italy.ORCID 0000-0003-2765-4840
Francesco TommasinoTrento Institute for Fundamental Physics and Applications (TIFPA), National Institute for Nuclear Physics, (INFN), 38123 Trento, Italy.ORCID 0000-0002-8684-9261
Thomas FriedrichDepartment of Biophysics, GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany.ORCID 0000-0003-0074-6390
Michael KrämerDepartment of Biophysics, GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany.
Michael ScholzDepartment of Biophysics, GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany.ORCID 0000-0002-6382-6737
Giuseppe BattistoniDepartment of Physics, University of Trento, 38123 Trento, Italy.ORCID 0000-0003-3484-1724
Alessia Embriaco"Pavia" Section, INFN-National Institute for Nuclear Physics, 6-27100 Pavia, Italy.
Davide ChiapparaLaboratori Nazionali del Sud, INFN-National Institute for Nuclear Physics, 95125 Catania, Italy.
Giuseppe A P CirroneLaboratori Nazionali del Sud, INFN-National Institute for Nuclear Physics, 95125 Catania, Italy.ORCID 0000-0001-5733-9281
Giada PetringaLaboratori Nazionali del Sud, INFN-National Institute for Nuclear Physics, 95125 Catania, Italy.ORCID 0000-0002-2854-8436
Marco DuranteDepartment of Biophysics, GSI Helmholtzzentrum für Schwerionenforschung, 64291 Darmstadt, Germany.ORCID 0000-0002-4615-553X
Emanuele ScifoniTrento Institute for Fundamental Physics and Applications (TIFPA), National Institute for Nuclear Physics, (INFN), 38123 Trento, Italy.ORCID 0000-0003-1851-5152
Istituto Nazionale di Fisica Nucleare · ITGSI Helmholtz Centre for Heavy Ion Research · DEInstitute of Nuclear Physics, Polish Academy of Sciences · PLUniversity of Trento · IT

Funding

Istituto Nazionale di Fisica Nucleare MoVe IT CSNV
6 · The paper itself

Abstract

Clinical routine in proton therapy currently neglects the radiobiological impact of nuclear target fragments generated by proton beams. This is partially due to the difficult characterization of the irradiation field. The detection of low energetic fragments, secondary protons and fragments, is in fact challenging due to their very short range. However, considering their low residual energy and therefore high LET, the possible contribution of such heavy particles to the overall biological effect could be not negligible. In this context, we performed a systematic analysis aimed at an explicit assessment of the RBE (relative biological effectiveness, i.e., the ratio of photon to proton physical dose needed to achieve the same biological effect) contribution of target fragments in the biological dose calculations of proton fields. The TOPAS Monte Carlo code has been used to characterize the radiation field, i.e., for the scoring of primary protons and fragments in an exemplary water target. TRiP98, in combination with LEM IV RBE tables, was then employed to evaluate the RBE with a mixed field approach accounting for fragments' contributions. The results were compared with that obtained by considering only primary protons for the pristine beam and spread out Bragg peak (SOBP) irradiations, in order to estimate the relative weight of target fragments to the overall RBE. A sensitivity analysis of the secondary particles production cross-sections to the biological dose has been also carried out in this study. Finally, our modeling approach was applied to the analysis of a selection of cell survival and RBE data extracted from published in vitro studies. Our results indicate that, for high energy proton beams, the main contribution to the biological effect due to the secondary particles can be attributed to secondary protons, while the contribution of heavier fragments is mainly due to helium. The impact of target fragments on the biological dose is maximized in the entrance channels and for small α/β values. When applied to the description of survival data, model predictions including all fragments allowed better agreement to experimental data at high energies, while a minor effect was observed in the peak region. An improved description was also obtained when including the fragments' contribution to describe RBE data. Overall, this analysis indicates that a minor contribution can be expected to the overall RBE resulting from target fragments. However, considering the fragmentation effects can improve the agreement with experimental data for high energy proton beams.

Indexed as

biophysical dose-response modelsmixed field modelMonte Carloproton therapyrelative biological effectiveness (RBE)TOPAS

Identifiers

PMID34638254
PMCPMC8507563
OpenAlexW3201650296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.